Amgen filed a Worker Adjustment and Retraining (WARN) filing with the Commonwealth of Massachusetts, indicating the company planned to lay off 149 employees effective December 31, 2019.
Roche is testing the company’s “brain shuttle” in humans, with the Swiss drugmaker hoping to rejuvenate the theory that removing amyloid plaques from the brains of patients with Alzheimer’s disease will prove effective despite repeated failures.
Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.
Amgen Inc. said competition for the company’s older drugs sent third-quarter 2019 revenue down 3 percent, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.
Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.
Indianapolis-based Eli Lilly announced the closing of the company’s Surrey, U.K.-based Erl Wood neuroscience research center by the end of 2020, affecting 270 staffers.
The U.S. Food and Drug Administration approved Eli Lilly and Co.’s Reyvow, representing the first new class of acute migraine treatment approved by the regulatory agency in more than two decades.
Evotec SE announced a strategic multi-year collaboration with Takeda Pharmaceutical Company Limited to establish at least five drug discovery programs across multiple therapeutic areas.
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
Emory University in Georgia fired a husband and wife neuroscience research team after they were accused of failing to disclose ties to China that included financial funding.